Annual D&A
$44.20 K
-$160.50 K-78.41%
30 September 2023
Summary:
Outlook Therapeutics annual depreciation & amortization is currently $44.20 thousand, with the most recent change of -$160.50 thousand (-78.41%) on 30 September 2023. During the last 3 years, it has fallen by -$217.90 thousand (-83.14%). OTLK annual D&A is now -98.69% below its all-time high of $3.36 million, reached on 30 September 2019.OTLK Depreciation And Amortization Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly D&A
$28.70 K
+$500.00+1.77%
30 June 2024
Summary:
Outlook Therapeutics quarterly depreciation & amortization is currently $28.70 thousand, with the most recent change of +$500.00 (+1.77%) on 30 June 2024. Over the past year, it has increased by +$17.50 thousand (+156.25%). OTLK quarterly D&A is now -97.02% below its all-time high of $962.40 thousand, reached on 30 September 2015.OTLK Quarterly D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM D&A
$96.30 K
+$17.50 K+22.21%
30 June 2024
Summary:
Outlook Therapeutics TTM depreciation & amortization is currently $96.30 thousand, with the most recent change of +$17.50 thousand (+22.21%) on 30 June 2024. Over the past year, it has increased by +$52.10 thousand (+117.87%). OTLK TTM D&A is now -97.14% below its all-time high of $3.36 million, reached on 30 September 2019.OTLK TTM D&A Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
OTLK Depreciation And Amortization Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +156.3% | +117.9% |
| 3 y3 years | -83.1% | -43.4% | -63.3% |
| 5 y5 years | -98.7% | -96.8% | -97.1% |
OTLK Depreciation And Amortization High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -83.1% | at low | -44.3% | +165.7% | -63.3% | +117.9% |
| 5 y | 5 years | -98.7% | at low | -96.8% | +165.7% | -97.1% | +117.9% |
| alltime | all time | -98.7% | at low | -97.0% | +165.7% | -97.1% | +117.9% |
Outlook Therapeutics Depreciation And Amortization History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2024 | - | $28.70 K(+1.8%) | $96.30 K(+22.2%) |
| Mar 2024 | - | $28.20 K(0.0%) | $78.80 K(+27.9%) |
| Dec 2023 | - | $28.20 K(+151.8%) | $61.60 K(+39.4%) |
| Sept 2023 | $44.20 K(-78.4%) | $11.20 K(0.0%) | $44.20 K(-47.7%) |
| June 2023 | - | $11.20 K(+1.8%) | $84.50 K(-32.2%) |
| Mar 2023 | - | $11.00 K(+1.9%) | $124.60 K(-24.3%) |
| Dec 2022 | - | $10.80 K(-79.0%) | $164.70 K(-19.6%) |
| Sept 2022 | $204.70 K(-21.9%) | $51.50 K(+0.4%) | $204.80 K(+0.4%) |
| June 2022 | - | $51.30 K(+0.4%) | $204.00 K(+1.5%) |
| Mar 2022 | - | $51.10 K(+0.4%) | $200.90 K(-13.4%) |
| Dec 2021 | - | $50.90 K(+0.4%) | $232.00 K(-11.5%) |
| Sept 2021 | $262.10 K(-52.7%) | $50.70 K(+5.2%) | $262.20 K(-10.1%) |
| June 2021 | - | $48.20 K(-41.4%) | $291.60 K(-20.3%) |
| Mar 2021 | - | $82.20 K(+1.4%) | $365.70 K(-20.5%) |
| Dec 2020 | - | $81.10 K(+1.2%) | $459.80 K(-17.0%) |
| Sept 2020 | $554.10 K(-83.5%) | $80.10 K(-34.5%) | $554.00 K(-59.3%) |
| June 2020 | - | $122.30 K(-30.6%) | $1.36 M(-34.3%) |
| Mar 2020 | - | $176.30 K(+0.6%) | $2.07 M(-23.6%) |
| Dec 2019 | - | $175.30 K(-80.3%) | $2.71 M(-19.3%) |
| Sept 2019 | $3.36 M | $888.90 K(+6.7%) | $3.36 M(+2.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2019 | - | $833.40 K(+2.1%) | $3.30 M(+0.3%) |
| Mar 2019 | - | $816.50 K(-0.8%) | $3.29 M(+2.7%) |
| Dec 2018 | - | $823.10 K(-0.2%) | $3.20 M(+4.8%) |
| Sept 2018 | $3.05 M(+13.5%) | $824.40 K(+0.3%) | $3.05 M(+5.3%) |
| June 2018 | - | $822.10 K(+12.4%) | $2.90 M(+5.5%) |
| Mar 2018 | - | $731.30 K(+8.1%) | $2.75 M(+1.9%) |
| Dec 2017 | - | $676.60 K(+1.0%) | $2.70 M(+0.3%) |
| Sept 2017 | $2.69 M(+12.4%) | $670.10 K(-0.3%) | $2.69 M(+2.5%) |
| June 2017 | - | $672.10 K(-1.2%) | $2.63 M(+2.9%) |
| Mar 2017 | - | $680.20 K(+1.6%) | $2.55 M(+3.3%) |
| Dec 2016 | - | $669.80 K(+11.0%) | $2.47 M(+3.2%) |
| Sept 2016 | $2.39 M(+31.2%) | $603.60 K(+0.8%) | $2.39 M(-13.0%) |
| June 2016 | - | $598.60 K(+0.1%) | $2.75 M(+6.9%) |
| Mar 2016 | - | $598.10 K(+0.7%) | $2.58 M(+17.3%) |
| Dec 2015 | - | $594.00 K(-38.3%) | $2.20 M(+20.4%) |
| Sept 2015 | $1.82 M(+107.7%) | $962.40 K(+128.5%) | $1.82 M(+111.6%) |
| June 2015 | - | $421.20 K(+92.3%) | $862.30 K(+95.5%) |
| Mar 2015 | - | $219.00 K(-1.4%) | $441.10 K(+98.6%) |
| Dec 2014 | - | $222.10 K | $222.10 K |
| Sept 2014 | $878.50 K | - | - |
FAQ
- What is Outlook Therapeutics annual depreciation & amortization?
- What is the all time high annual D&A for Outlook Therapeutics?
- What is Outlook Therapeutics quarterly depreciation & amortization?
- What is the all time high quarterly D&A for Outlook Therapeutics?
- What is Outlook Therapeutics quarterly D&A year-on-year change?
- What is Outlook Therapeutics TTM depreciation & amortization?
- What is the all time high TTM D&A for Outlook Therapeutics?
- What is Outlook Therapeutics TTM D&A year-on-year change?
What is Outlook Therapeutics annual depreciation & amortization?
The current annual D&A of OTLK is $44.20 K
What is the all time high annual D&A for Outlook Therapeutics?
Outlook Therapeutics all-time high annual depreciation & amortization is $3.36 M
What is Outlook Therapeutics quarterly depreciation & amortization?
The current quarterly D&A of OTLK is $28.70 K
What is the all time high quarterly D&A for Outlook Therapeutics?
Outlook Therapeutics all-time high quarterly depreciation & amortization is $962.40 K
What is Outlook Therapeutics quarterly D&A year-on-year change?
Over the past year, OTLK quarterly depreciation & amortization has changed by +$17.50 K (+156.25%)
What is Outlook Therapeutics TTM depreciation & amortization?
The current TTM D&A of OTLK is $96.30 K
What is the all time high TTM D&A for Outlook Therapeutics?
Outlook Therapeutics all-time high TTM depreciation & amortization is $3.36 M
What is Outlook Therapeutics TTM D&A year-on-year change?
Over the past year, OTLK TTM depreciation & amortization has changed by +$52.10 K (+117.87%)